EDBI

Founded 1991
Founders Michael D. Laufer

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 114
Average round size
info
The average size of a deal this fund participated in
$59M
Portfolio companies 103
Rounds per year 3.80
Lead investments 19
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.24
Exits 26
Key employees 8
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Pharmaceutical
  • Medical
Summary

EDBI appeared to be the VC, which was created in 1991.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Bitmain Technologies, Moderna Therapeutics, Magic Leap We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the EDBI, startups are often financed by Sequoia Capital India, Qualcomm Ventures, Accel. The meaningful sponsors for the fund in investment in the same round are Temasek Holdings, Intel Capital, Sequoia Capital India. In the next rounds fund is usually obtained by New Enterprise Associates, Delphi Ventures, West Health Investment Fund.

Besides them, we counted 16 critical employees of this fund in our database.

Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. When the investment is from EDBI the average startup value is more than 1 billion dollars. This EDBI works on 9 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2018.

Read more

Funds with similar focus

Funds from Singapore, Singapore
Funds with similar focus located in Singapore, Singapore:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

VNLIFE

E-Commerce
FinTech
Logistics
Payments
Tourism
1
$250M30 Jul 2021 Vietnam, Hanoi

Nature’s Fynd

Agriculture
AgTech
Food and Beverage
Food Processing
Sustainability
1
$350M19 Jul 2021 United States, Chicago

MiRXES Pte Ltd

Biotechnology
Health Care
Life Science
1
$77M08 Jul 2021

AvePoint

Cloud Computing
Compliance
Document Management
SaaS
Security
Software
n/a
$140M02 Jul 2021 United States, Jersey City

SCI Ecommerce

E-Commerce
E-Commerce Platforms
Internet
n/a
$28M01 Jul 2021 Singapore, Singapore

Nuevocor

Biopharma
Biotechnology
Medical
Pharmaceutical
1
$24M18 Jun 2021 Singapore, Singapore

Biotechnology
1
$200M26 May 2021

Cityneon

Electronics
Service Industry
1
$173M21 Apr 2021

ImmunoScape

Biotechnology
Life Science
Medical
n/a
$14M14 Apr 2021 Singapore, Singapore
News
Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

– Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10m Series A led by Openspace Ventures and EDBI.
– The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston.
– Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai, the Japanese pharmaceutical that led Neuroglee’s last round last year.
– Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.

Doctor Anywhere Raises US$65.7M in Series C Financing

– Doctor Anywhere from Singapore develops a tech-led healthcare company.
– The company raised US$65.7M in Series C funding.
– The round was led by Asia Partners and also joined by Novo Holdings A/S, Philips Venture, OSK-SBI Ventures and existing investors Square Peg, EDBI, IHH Healthcare, Kamet Capital and Pavilion Capital.
– The new investment will be used to bolster the company’s market leadership, to further deepen its presence in its existing markets, and to expand into new markets.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent EDBI?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: